Ocular melanoma research IDEAYA Biosciences has announced a major milestone in its ongoing clinical trials for the combination therapy of darovasertib and crizotinib, specifically targeting first-line HLA-A2-negative metastatic uveal melanoma (MUM). This breakthrough highlights the company’s commitment to innovative cancer treatments and precision medicine. Key Points: IDMC Recommendation: The Independent Data Monitoring Committee (IDMC) [...]